Author

H Wu

Observed name: Hsiaohui Wu

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5110244820

DOP16 Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension

2024 · C Siegel, S Danese, et al. · Journal of Crohn s and Colitis · 4

PDF

DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients

2023 · A Dignass, M Regueiro, et al. · Journal of Crohn s and Colitis · 4

DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study

2023 · S Danese, M T Abreu, et al. · Journal of Crohn s and Colitis · 4

PDF

P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension

2023 · R Panaccione, S Danese, et al. · Journal of Crohn s and Colitis · 4

Emerging Trends in US Oncological Approvals: A 13-Year Review (1999–2011)

2012 · Jing Huang, Wenze Zhang, et al. · Drug Information Journal · 3

DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

2024 · S W Schreiber, B G Feagan, et al. · Journal of Crohn s and Colitis · 2

PDF

P773 Extended induction in the True North open-label extension study: clinical outcomes of ~2 years of ozanimod treatment

2023 · S Vermeire, J F Colombel, et al. · Journal of Crohn s and Colitis · 2

P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis

2023 · R Panaccione, S Danese, et al. · Journal of Crohn s and Colitis · 2

PDF

P687 Durability of recaptured response to ozanimod during the True North open-label extension

2023 · A Dignass, M Regueiro, et al. · Journal of Crohn s and Colitis · 1

PDF

P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study

2023 · S Vermeire, J F Colombel, et al. · Journal of Crohn s and Colitis · 1

PDF

P637 Ozanimod efficacy with or without concomitant corticosteroids in 5-ASA–exposed, advanced therapy–naive, immunomodulator-naive patients with ulcerative colitis: a post hoc analysis of True North

2024 · S Horst, M Fischer, et al. · Journal of Crohn s and Colitis

PDF

P789 Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis

2024 · B Siegmund, T Kuehbacher, et al. · Journal of Crohn s and Colitis

PDF

P567 Impact of recent thiopurine use on ozanimod safety in patients with ulcerative colitis: a post hoc analysis of the phase 3 True North study

2024 · R Battat, R Panaccione, et al. · Journal of Crohn s and Colitis

PDF

DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study

2023 · S Vermeire, A Dignass, et al. · Journal of Crohn s and Colitis

PDF

P719 Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatment

2023 · S Danese, M T Abreu, et al. · Journal of Crohn s and Colitis

PDF

Works count: 15

Citation count: 27

H-index: 4

I10-index: